Trials / Completed
CompletedNCT03361969
Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
A Double-blind, Randomised, Placebo-controlled, Multi-center Study to Evaluate Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Pantarhei Oncology B.V. · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase IIa, double-blind, randomised, placebo-controlled, multi-center study to evaluate the effects of estetrol on testosterone suppression and quality of life in prostate cancer patients treated with an LHRH agonist. Patients will be treated with estetrol or placebo for 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Estetrol | estetrol formulated in tablets |
| DRUG | Placebo Oral Tablet | placebo tablets |
Timeline
- Start date
- 2018-04-16
- Primary completion
- 2020-05-15
- Completion
- 2020-05-15
- First posted
- 2017-12-05
- Last updated
- 2021-06-18
Locations
6 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03361969. Inclusion in this directory is not an endorsement.